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Background: Despite the success of tamoxifen since its introduction, about one-third of patients with estrogen (ER)
and/or progesterone receptor (PgR) - positive breast cancer (BC) do not benefit from therapy. Here, we aim to
identify molecular mechanisms and protein biomarkers involved in tamoxifen resistance.
Results: Using iTRAQ and Immobilized pH gradient-isoelectric focusing (IPG-IEF) mass spectrometry based proteomics we
compared tumors from 12 patients with early relapses (<2 years) and 12 responsive to therapy (relapse-free > 7 years). A
panel of 13 proteins (TCEAL4, AZGP1, S100A10, ALDH6A1, AHNAK, FBP1, S100A4, HSP90AB1, PDXK, GFPT1, RAB21, MX1,
CAPS) from the 3101 identified proteins, potentially separate relapse from non-relapse BC patients. The proteins in the
panel are involved in processes such as calcium (Ca2+) signaling, metabolism, epithelial mesenchymal transition (EMT),
metastasis and invasion. Validation of the highest expressed proteins in the relapse group identify high tumor levels of
CAPS as predictive of tamoxifen response in a patient cohort receiving tamoxifen as only adjuvant therapy.
Conclusions: This data implicate CAPS in tamoxifen resistance and as a potential predictive marker.
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Consensus guidelines for adjuvant breast cancer (BC)
therapy advise different treatment modalities to diminish
the risk of recurrence after surgery for primary breast
cancer [1]. Factors taken into account beside stage of the
disease are histopathological parameters, expression of
steroid receptors, overexpression or amplification of
HER2, and proliferation. Adjuvant endocrine therapy for
a minimum of five years postoperatively is advised to pa-
tients with BC expressing estrogen and/or progesterone
receptors (ER and PgR) and half the recurrence rate in
this group. However, about a third of the eligible pa-
tients will relapse during or after tamoxifen therapy and
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unless otherwise stated.effort has been made to find markers to endocrine ther-
apy, see Musgroove and Sutherland for a review [3].
Following the work by Sørlie and colleagues that pre-
sented the intrinsic molecular subgroups of BC based on
gene expression patterns, a substantial amount of infor-
mation has elucidated the complexity in pathways driv-
ing the different BC subgroups. The intrinsic subgroups
differ molecularly, in prognosis as well as relapse rates
after different therapy modalities [4]. The two luminal
subgroups originating from the well differentiated luminal
layer are exclusively ER positive and have in general a fa-
vorable prognosis. However, there is a substantial hetero-
geneity within the ER positive groups where luminal B has
been characterized by a more aggressive disease course
compared to luminal A in terms of recurrence rate which
could partly be explained by the proportion of HER2 posi-
tive patients in this group [4]. Genomic studies have great
impact on BC classification enabling the identification oftral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Clinicopathological characteristics of patients
included in the discovery proteomics
Feature Control n =12 Relapse n = 12
Planned tamoxifen regimen
2 years 1 5





















All patients were ER positive and received adjuvant tamoxifen as the only
systemic adjuvant treatment.
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sequently taking us a step closer to personalizing therapy.
Proteomics is a mean of complementing the genomics
information since mRNA and protein levels don’t always
correlate [5]. Several different proteins and signaling
pathways have been suggested to be part of the tamoxi-
fen resistance mechanism, for example kinase expression
levels and activity, transcription factors and their coregu-
lators, as well as downstream intracellular events as the
PIK3/AKT/mTOR pathway [3,6]. In addition, other nu-
clear receptors, as the retinoic acid receptor alpha are
involved in tamoxifen resistance [7].
Apart from binding and inhibiting ER, tamoxifen also
bind and inhibit the calcium binding protein calmodulin
(CALM) [8,9]. CALM regulates many cellular protein
kinases, phosphatases and transmembrane ion trans-
porters, mainly in a calcium dependent manner. CALM
interacts and modulate ER activity [10]. Another mem-
ber of the EF hand motif family is Calcyphosine (CAPS) -
for calcium binding and regulated by cyclic AMP through
phosphorylation protein. CAPS has been suggested as an
alternative calcium signaling route to CALM [11]. CAPS
have high levels in endometrial tumors, whose prolifera-
tion is known to be induced by tamoxifen, compared to
normal proliferative tissue [12].
Here we use mass spectrometry (MS)-based proteo-
mics to discover potential predictive biomarkers for ad-
juvant tamoxifen therapy in a patient population that
received adjuvant tamoxifen as the only systemic adjuvant
therapy. We identified 13 proteins showing significant dif-
ferential expression in relapsing patients compared to our
defined control group. These were involved in processes
such as calcium (Ca2+) signaling, metabolism, epithelial
mesenchymal transition, metastasis and invasion [12-14].
Validation of calcyphosine (CAPS) in the entire clinical
cohort suggests that high levels predict relapse, and that
CAPS is a potential predictor of tamoxifen response.
Results
Experimental design and mass spectrometry based
proteomic
To do an unbiased search for tamoxifen predictive
markers, we performed quantitative proteomics on tumor
homogenates from BC patients. We selected tumors from
12 patients who relapsed within 2 years of tamoxifen
treatment (referred to as relapse) and 12 patients with a
disease-free follow up time of more than 7 years (referred
to as control). Patients were matched into 12 pairs defined
by age, tumor size, and node status. All patients were
ductal and ER positive cancers (Table 1). Quantitative
mass spectrometry based proteomics on these patient
samples was performed by nanoLC-MS/MS using LTQ-
Orbitrap Velos mass spectrometer on fractions from pep-
tide isoelectric focusing, pH 3.4–4.8. See Figure 1A forworkflow. MS based proteomics yielded a total of 3101
identified proteins, of which 550 overlapped between all
the 4 iTRAQ sets and used in the analysis (Additional
file 1).
Statistical analysis of proteomics data to identify
tamoxifen-predictive markers
Uni- and multivariate analysis by SAM and OPLS were
used to identify potential tamoxifen predictive markers
[15,16]. These statistical analyses revealed a 13 protein
signature, which could separate relapse vs. control
groups, P-value 2.2e-005 (Figure 1B). Principal component
analysis (PCA) displayed no bias between and within the
relapse and control groups (Additional file 2A-C). Protein
identities and iTRAQ protein quantities of the potential
13 protein signature are shown in Figure 1C. Many of the
proteins in the 13 protein panel have been connected to
BC and other cancer types before (Table 2). There is con-
nection to EMT via S100A4, an EMT marker, as well as
S100A10 and AHNAK, who are protein complex compo-
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Figure 1 Putative tamoxifen predictive proteins. (A) Proteomics discovery workflow. (B) Score scatter plot from uni- and multivariate analysis,
separating 12 matched pairs of control and relapse patients based on a 13 protein signature. Numbers indicate matched patient pairs. C (black)
for control (>7 years of disease free follow up) and R (red) for relapse (within 2 years) patients. P = 2.2e-005. (C) Quantitative iTRAQ proteomics
data showing the differences between control and relapse patients for the 13 proteins. Abbreviation: IPG-IEF, immobilized pH gradient – isoelectric
focusing.
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tumor homogenates
A positive selection marker is generally preferred over a
negative marker and since our aim was to identify pa-
tients relapsing on tamoxifen, we choose to verify ex-
pression of the 2 proteins with the highest expression
ratio in the relapse group, CAPS and MX1, from the
proteomics data (Figure 1C). An initial verification was
performed by western blot (WB) on four randomly se-
lected matched pairs of cytosols from all 24 patients in-
cluded in the study. The WB showed that both CAPS
and MX1 had overall higher protein levels in the relapse
group compared to control (Figure 2A). Correlation be-
tween MS and WB data were 0.8 R2 (p = 0.0037) for
CAPS and 0.6 R2 (p = 0.024) for MX1 (Additional file 3).
Based on this small verification we performed protein
quantification by ELISA for CAPS and MX1 on 79 and
89 breast tumor homogenates respectively. See Table 3
for clinical characteristics. Relapse-free survival (RFS)
and breast cancer-specific survival (BCS) were used asprimary end points, based on the time from diagnosis to
the first event of loco-regional or distant recurrence, and
time from diagnosis to breast cancer death, respectively.
High protein levels of CAPS was associated with
increased RFS (p = 0.049, 85% power) and BCS
(p = 0.11, 80% power) (Figure 2B, C). Selection of
lower tertile vs. the 2 higher tertiles for CAPS was
done based on difference in HR to continuous data
(Additional file 4). MX1 protein levels were not
correlated to RFS or BCS in this clinical cohort
(Additional file 5).
CAPS remained an independent prognostic marker
in a Cox proportional multivariate analysis for RFS
(HR = 3.6; p = 0.011), while nodal status (node-negative
versus node-positive) (HR = 1.7; p = 0.22), tumor size
(<20 mm versus ≥ 20 mm) (HR = 1.4; p = 0.43), age
(HR = 1.0; p = 0.87), ER (HR = 0.88; p = 0.073) and PgR
(HR = 0.96; p = 0.48) were not (Table 4). CAPS was
also statistical significant factor in multivariate analysis
for BCS (HR = 4.0 p = 0.043). Despite a total of 29
Table 2 Connection of the 13 protein panel to cancer
Protein Connection to cancer References
TCEAL4 Transcription elongation factor A (SII) like 4 (TCEAL4) is down-regulated in anaplastic thyroid cancer. [34]
AZGP1 Stimulates lipid degradation. AZGP1 is a tumor suppressor in pancreatic cancer inducing mesenchymal-to-epithelial
(MET) transdifferentiation by inhibiting TGF-β-mediated ERK signaling. The percentage of IHC positive stained cells in
(Pancreatic Intraepithelial Neoplasia) PanIN lesions, primary and metastatic PDAC, gradually decreases from 48 to 26
and 5%, respectively.
[35]
More malignant breast tumors showed downregulated AZGP1 mRNA. [36]
Low AZGP1 expression, by IHC, was associated with clinical recurrence in prostate cancer. [37]
S100A10 S100A10 was down-regulated in breast cancer, irrespective of pathological stage. [38]
Complex with AnnexinA2 and AHNAK and E-cadherin at the plasma membrane. [26,27]
S100A10 is required for recruitment of macrophages to tumor sites and tumor growth. [39]
ALDH6A1 Catalyzes the irreversible oxidative decarboxylation of malonate and methylmalonate semialdehydes to acetyl- and
propionyl-CoA. Decreased expression with increasing grade in kidney cancer.
[40]
AHNAK Associates with S100A10 and E-cadherin at the plasma membrane. [26]
FBP1 Converts fructose-1,6-bisphosphate to fructose 6-phosphate in gluconeogenesis. Antagonize glycolysis. Downregulated
through NF-kappaB pathway in Ras-transformed NIH3T3 cells. Restoration of FBP1 expression suppressed
anchorage-independent growth.
[41]
Loss of FBP1 by Snail-G9a-Dnmt1 complex increase glucose uptake, glycolysis and induce a cancer stem cell like
characteristics.
[31]
S100A4 Involved in regulation of angiogenesis, cell survival, motility, and invasion. EMT marker. [28,42,43]
Staining for S100A4 is associated with poorer survival in BC. [44]
HSP90AB1 High levels of HSP90AB1 correlates with poor prognosis in HER2-/ER+ BC. [45]
GFPT1 Rate-limiting enzyme of hexosamine biosynthetic pathway (HBP). [29]
IHC analysis indicated elevated GlcNAcylation levels in breast tumor tissue as compared to adjacent tissue. GlcNAcylation
was significantly enhanced in metastatic lymph nodes compared with their corresponding primary tumor tissues.
[30]
BC cells upregulate HBP, including increased O-GlcNAcation and elevated expression of O-GlcNAc transferase (OGT),
which is the enzyme catalyzing the addition of O-GlcNAc to proteins.
[46]
PDXK Required for synthesis of pyridoxal-5-phosphate from vitamin B6. pyridoxal-5-phosphate is a prosthetic group of some
enzymes.
RAB21 Overexpression stimulates cell migration. Small GTPase Rab21 regulates cell adhesion and controls endosomal traffic of
β1-integrins.
[47]
Rab21 is required for Carcinoma-associated fibroblasts (CAFs) to promote the invasion of cancer cells. RAB21 enables
the accumulation of integrin a5 at the plasma membrane and subsequent force-mediated matrix remodelling.
[48]
MX1 Stable exogenous MX1 expression inhibited in vitro motility and invasiveness of human prostate carcinoma cell line
PC-3 M.
[49]
Upregulated in a mammary carcinoma xenograft model of tamoxifen resistance. [23]
Upregulated in a fulvestrant-resistant cell line T47D-r on the mRNA and protein level compared to T47D. [24]
CAPS High expression gives bad prognosis in endometrial cancer. [21]
Over-expressed in ovarian cancer. [50]
Upregulated 30× in MCF7 ErbB2 compared to MCF7. [51]
Phosphorylation substrate for protein kinase A. [11,52]
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among the 79 patients with data on CAPS.
Receiver operator characteristic (ROC) for CAPS
yielded an area of 0.62 (p = 0.08) and 0.58 (p = 0.29) for
RFS and BCS, respectively (Additional file 6).
Discussion
The vast majority of BC patients are ER positive,
making them eligible for adjuvant endocrinetreatment. Tamoxifen has been the corner stone in
breast cancer treatment since 40 years, although in
part replaced with the aromatase inhibitors (AI)
during the last decade. However, due to the marginal
benefit and the severe side effects accomplished with
aromatase inhibitor therapy, tamoxifen still plays
an important role in breast cancer treatment.
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Figure 2 Verification of proteomics data and identification of CAPS as a potential predictive marker for early relapse of breast cancer
patients receiving tamoxifen. (A) Western blot of 4 matched pairs of patients, randomly selected from the discovery set to verify CAPS and
MX1 expression. (B) Relapse free survival (p = 0.049) and (C) Breast cancer survival (p = 0.11) of patients receiving adjuvant tamoxifen. Patients
were divided by CAPS expression into lower tertile and 2 upper tertiles. See Table 2 for patient characteristics for (B) and (C).
Table 3 Clinicopathological characteristics of patients
included in the validation cohort
Feature Nr (%) CAPS




<50 21 (27%) 9.6 14.6 22.3
≥50 58 (73%) 18.7 21 38.4 0.0049
Tumor size 45 (57%) 18.2 25.5 36.1
T1
T2–3 34 (43%) 11.5 20.1 31.2 0.15
S-phase
<10% 50 (78%) 16.5 25.5 33
≥10% 14 (22%) 8.5 19.7 42.9 0.29
Missing 15
Lymph-node status
Node-negative 42 (56%) 17.4 24.8 38.9
Node positive 33 (44%) 12.6 24.3 32.0 0.33
Missing 4
PgR (fmol/μg DNA)
Neg (≤0.09) 23 (29%) 14.8 30.5 38.9
Pos (>0.09) 56 (71%) 14.6 24.3 29.7 0.58
All patients were ER positive (Average ER = 4.4 fmol/μg DNA) and received
adjuvant tamoxifen as the only systemic adjuvant treatment. CAPS protein
levels were determined by ELISA (n = 79). Mann-Whitney’s test for significance.
Abbreviation: PgR, progesterone receptor.
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to decipher the complex molecular events that are re-
sponsible for the heterogeneity within subgroups of this
disease [17]. In this study we compared the protein dif-
ferences between patients with a relapse-free survival of
more than 7 years and those exhibiting a relapse within
2 years of tamoxifen treatment. We identified a potential
signature of 13 proteins that was able to significantly dif-
ferentiate relapsing patients from our defined control
group (Figure 1) Expression analysis of the 2 proteins
with highest levels in the relapse group confirmed that
high levels of CAPS, but not MX1, to be related to tam-
oxifen non-responsive patients.
High levels of CAPS were statistically significantly cor-
related to lower RFS both in uni- and multivariate ana-
lyses, including important breast cancer prognostic
markers as nodal status, tumor size, age and ER and PgR
levels. Several gene array based tests are validated and
commercially available for breast cancer care. Some are
developed to gain information about endocrine therapy.
The Oncotype dx separates patients where endocrine
therapy solely is enough versus patients that are in need
of additional chemotherapy [18]. The majority of markers
included in these profiles have been linked to prolifera-
tion. Endopredict can identify ER+, HER2 negative pa-
tients with an increased likelihood of development of late
distant metastasis [19]. Interestingly, Endopredict include
CALM2, a Ca2+ binding protein. Our ROC analysis also
indicates that CAPS protein levels needs to be used to-
gether with other markers to obtain good sensitivity and
Table 4 Univariate and Cox proportional multivariate analyses for recurrence (n = 29) and breast cancer death (n = 17)
in the 79 patients validation cohort with ER positive breast cancer, treated with tamoxifen only as systemic adjuvant
therapy
VARIABLES RFS BCS
HR 95% CI p-value HR 95% CI p-value
Univariate Lower Upper Lower Upper
Tumor size (T1 vs. T2–3) 1.4 0.67 2.9 0.37 1.3 0.48 3.3 0.63
Node status (pos vs neg) 2.1 0.97 4.6 0.059 5.3 1.51 18.7 0.0092
CAPS (high vs low) 2.4 0.98 6.0 0.049 2.8 0.80 9.6 0.11
Age (<50 vs ≥50 years) 1.00 0.97 1.03 0.82 1.01 0.98 1.05 0.60
ER cont (fmol/μg DNA) 0.87 0.77 0.98 0.026 0.76 0.60 0.95 0.018
PgR cont (fmol/μg DNA) 0.93 0.84 1.03 0.16 0.85 0.71 1.01 0.061
CAPS (high vs low) 2.4 0.98 6.0 0.056 2.8 0.80 9.6 0.11
Multivariate
Tumor size (T1 vs T2–3) 1.4 0.61 3.2 0.43 0.90 0.30 2.7 0.85
Node status (pos vs neg) 1.7 0.72 4.0 0.22 4.7 1.24 18.0 0.024
CAPS (high vs low) 3.6 1.3 9.7 0.011 4.0 1.04 15.1 0.043
Age (<50 vs ≥50 years) 1.00 0.97 1.03 0.87 1.02 0.99 1.06 0.24
ER cont (fmol/μg DNA) 0.88 0.76 1.01 0.073 0.72 0.55 0.96 0.025
PgR cont (fmol/μg DNA) 0.96 0.87 1.07 0.48 0.92 0.77 1,11 0.40
CAPS (high vs low) 3.6 1.3 9.7 0.011 4.0 1.04 15.1 0.043
Abbreviations: RFS Relapse-free survival, BCS breast cancer-specific survival.
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clude CAPS as a prognostic factor with the clinical cohort
used in this study.
CAPS is a Ca2+ binding protein whose synthesis and
activation is induced by the cAMP cascade (PKA) and
connected to signaling for cellular proliferation and dif-
ferentiation [11]. Interestingly, tamoxifen also has effects
on Ca2+ signaling, aside from its antiestrogenic proper-
ties by binding to and inhibiting CALM activity [20].
Our data of CAPS overexpression in non-responsive pa-
tients raises the hypothesis that tamoxifen fails to inhibit
the calcium signaling response in the cell, and that high
CAPS expression can function as an alternative compen-
satory mechanism when CALM is inhibited. CAPS has
previously been suggested to be an alternative signaling
step to CALM [11]. Moreover, recent studies found
higher CAPS levels in endometrial cancer compared to
normal proliferative tissue [12,21]. It is of note that tam-
oxifen has been shown to increase the risk for endomet-
rial cancer due to proliferative effects of the drug in this
tissue [22].
The MX1 results are surprising since MX1 showed in-
creased mRNA and protein levels in tamoxifen and ful-
vestrant resistance models [23,24]. The number of psms
for quantification differs between the 4 iTRAQ sets, with
1, 3, 8, and 27 psms used for iTRAQ quantification,
which could have introduced quantification bias. How-
ever, the negative result for MX1 with ELISA is probablydue to antibody effects, i.e. different or mixed epitope
recognition by the antibody compared to proteomics
data. In comparison, CAPS had 28, 5, 21 and 14 psms
used for quantification in the 4 different iTRAQ 8plex
sets. Hence, CAPS had a more robust MS quantification
that is less sensitive to noise and more likely to identify
the major protein variant that will ease ELISA validation.
Previous studies using DNA microarrays and proteo-
mics have shown upregulation of MX1 in vivo and
in vitro in cells resistant to tamoxifen (in vivo) and to
the ER downregulator fulvestrant (in vitro) [23,24]. A re-
cent in vitro study implicated the proliferative PIK3/
AKT pathway as part of the regulatory cascade inducing
MX1 expression in response to IFNα [25]. The upregula-
tion of MX1 in the relapsing patients may be a conse-
quence of induction of growth signaling through various
pathways.
Some draw backs with the present study must be dis-
cussed. So far, proteomics have been very labor intensive
making discovery work in a large number of tumors dif-
ficult. The small sample set for the discovery phase po-
tentially increase putative markers without any value.
Larger test sets of at least 100 patients in each group are
probably needed for identification of more robust
markers. Another drawback is that lobular patients were
excluded. These patients are often ER positive and sub-
jected to adjuvant endocrine treatment, thus the role of
CAPS has to be studied in all ER positive breast cancer
Johansson et al. Clinical Proteomics  (2015) 12:8 Page 7 of 10types. However, an advantage of proteomics is the direct
identification of a particular protein, or a set of proteins,
which are measurable by more time-effective, simpler
and less costly routine analysis methods such as IHC
and ELISA in the clinic.
The potential 13 protein panel shows connection to
breast and other forms and cancer (Table 2). Among the
proteins, there is connection to invasion, motility and
epithelial mesenchymal transition (EMT) by RAB21,
MX1, S100A4, S100A10, AHNAK, AZGP1. S100A10,
AHNAK and E-cadherin form protein complexes on the
plasma membrane [26,27]. S100A4 (also known as FSP1
and MTS-1) is an EMT marker [28]. There is also a con-
nection to metabolic changes by GFPT1, PDXK, FBP1,
ALDH6A1 and AZGP1. GFPT1 is the rate limiting enzyme
into the hexosamine synthesis pathway and increased
downstream GlcNAcylation is increased in breast tissue
compared to normal tissue [29,30]. PDXK catalyze the syn-
thesis of the prosthetic group pyridoxal-5-phosphate from
vitamin B6. The Snail-G9a-DNMT1 protein complex has
been shown not only to decrease E-cadherin levels but also
FBP1, increasing glucose uptake, inducing glycolysis and
cancer stem cell like characteristics [31].
Conclusions
We have performed MS based proteomics on 12 tumors
from relapse and 12 tumors from control patients and
associated a 13 protein panel with tamoxifen resistance.
Validation of the highest expressed protein in the relapse
group, CAPS, in the whole cohort implicate CAPS as a
potential predictive factor in ER positive breast cancer
receiving adjuvant tamoxifen.
Methods
Patient characteristics and selection
The study investigate differences in protein expression
profile between patients exhibiting relapses within two
years of tamoxifen therapy (referred to as relapse group)
and patients with a relapse-free survival of more than
seven years (referred to as control group) included
twenty-four patients (12 patients in each group). The rea-
son for choosing a relapse-free period of more than 7 years
was to include the possible hang-over effect by tamoxifen.
In order to avoid bias from biological differences, the two
groups were matched for tumor size, nodal status, and
age. Only ductal cancers were included. Data on histo-
pathological grade was not available. These patients ori-
ginate from a BC material previously described in detail
[32]. In short, a total of 402 patients with ER positive BC
subjected to adjuvant tamoxifen as the only adjuvant sys-
temic therapy (no chemotherapy allowed) were identified
from a larger consecutive cohort of 711 patients diagnosed
with a primary breast stage I-III from 1991 to 1996. Pa-
tients with a locally advanced BC, displaying distantmetastases at diagnosis, or having received neoadjuvant
therapy, were excluded from the cohort of 402 patients.
The median age of patients included in the present study
was 61.6 years for the control group and 65.1 for the re-
lapse group. A description of these patients’ characteristics
is shown in Table 1. Being unable to retrieve S-phase data
for all 24 patients, this factor was excluded. The study was
approved by the research ethical boards of Linköping Uni-
versity Hospital, Linköping, Sweden. During the study
period, there was no requirement to receive an informed
consent from each patient for storage and usage of the
remaining tumor homogenates according to Swedish law.
Preparation of tumor homogenates
Representative tumor tissue was homogenized in a
microdismembrator (Braun, Melsungen, Germany) and
suspended in cold potassium phosphate buffer (5 mM,
pH 7.4, 10% glycerol v/v, 1 mM dithiothreitol). Superna-
tants containing the cytosolic fractions were collected
after refrigerated centrifugation at 20,000 g, used for
steroid receptor content analysis and stored at –70°C.
The pellet fractions were analyzed by the method of
Burton, in order to evaluate DNA concentration.
Sample preparation for mass spectrometry
Tumor homogenates (cytosols) were acetone precipi-
tated and pellets were dissolved in 1% SDS, which were
diluted to 0.1% before protein concentration determin-
ation with Bio-rad DC protein assay. Triethylammo-
niumbicarbonat was added to each sample to give a final
concentration of 0.5 M. Proteins were reduced by adding
tris-(2-carboxyethyl) phosphine (TCEP) and alkylated by
methyl methanethiosulfonate (MMTS). Trypsin (modi-
fied sequence grade, Promega, Madision WI, USA) was
added (1:20, trypsin:protein) and the samples were incu-
bated overnight at 37°C. iTRAQ labelling of the peptides
were done according to the manufacturer’s protocol (Ap-
plied Biosystems) and cleaned by a strata-X-C-cartridge
(Phenomenex). Four different iTRAQ 8plex sets was used
to include all patients, and the 4 sets were connected by 2
iTRAQ channels with pooled samples, one for the 12 con-
trols (PC) and one for the 12 relapse (PR) samples. Three
pairs of matched control (115, 116, 117) and relapse (118,
119, 121) samples were included together with the pooled
samples (113, 114) in each iTRAQ 8plex set.Peptide separation
The iTRAQ labelled peptides, 360 μg for each of the 4
iTRAQ sets, were separated by immobilized pH gradient -
isoelectric focusing (IPG-IEF) on a narrow range pH 3.4–
4.8 strip as described by Branca et al. [33]. Peptides were
extracted from the strips by a prototype liquid handling
robot, kindly supplied by GE Healthcare Bio-Sciences AB.
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50 μl of MQ was added to each well. After 30 minutes in-
cubation, the liquid was transferred to a 96 well plate and
the extraction was repeated 2 more times. The extracted
peptides were dried in speedvac and dissolved in 3% acet-
ronitrile (ACN), 0.1% formic acid.NanoLC-MS/MS analysis
Before analysis on the LTQ-Orbitrap Velos (Thermo
Fischer Scientific, San Jose, CA, USA), peptides were
separated using an Agilent 1200 nano-LC system. Sam-
ples were trapped on a Zorbax 300SB-C18, and sepa-
rated on a NTCC-360/100-5-153 (Nikkyo Technos., Ltd)
column using a gradient of A (3% ACN, 0.1% FA) and B
(95% ACN, 0.1% FA), ranging from 3% to 40% B in
45 min with a flow of 0.4 μl/min. The LTQ-Orbitrap
Velos was operated in a data-dependent manner, select-
ing 5 precursors for sequential fragmentation by CID
and HCD, and analyzed by the linear iontrap and orbi-
trap, respectively. The survey scan was performed in the
Orbitrap at 30.000 resolution (profile mode) from 300–
2000 m/z, using lock mass at m/z 445.120025, with a
max injection time of 500 ms and AGC set to 1 × 106
ions. For generation of HCD fragmentation spectra, a
max ion injection time of 500 ms and AGC of 2 × 105
were used before fragmentation at 50% normalized colli-
sion energy. For FTMS MS2 spectra, normal mass range
was used, centroiding the data at 7500 resolution. Pep-
tides for CID were accumulated for a max ion injection
time of 200 ms and AGC of 3 × 104, fragmented with
35% collision energy, wideband activation on, activation
q 0.25, activation time 10 ms before analysis at normal
scan rate and mass range in the linear iontrap. Precur-
sors were isolated with a width of 2 m/z and put on the
exclusion list for 60 s. Single and unassigned charge
states were rejected from precursor selection.Peptide and protein identification
All Orbitrap data was searched by Mascot 2.2 (Matrix
Science Limited, London, UK) under the software plat-
form Proteome Discoverer 1.1 (Thermo) against the hu-
man swissprot database (build 57.13) and results were
limited to a false discovery rate of <1%. Precursor mass
tolerance was set to 10 ppm, and product mass tolerances
of 0.015 Da for HCD-FTMS and 0.7 Da for CID-ITMS
were used. Oxidized methionine was set as dynamic modi-
fication and methylthio, N-terminal 8plex iTRAQ, and
lysyl 8plex iTRAQ as fixed modifications. Quantification
of iTRAQ 8plex reporter ions was done by Proteome
Discoverer on HCD-FTMS tandem mass spectra using an
integration window tolerance of 20 ppm. Proteins with 1
or more of 1% FDR confident peptides were used in the
following data analysis.Identification of potential biomarkers
Potential biomarkers were selected by multivariate ana-
lysis of the BC patient samples with orthogonal partial
least square (OPLS) analysis using Simca software, using
the S-plot and loading plot described by Wiklund et al.
2008 and univariate analysis corrected for multiple test-
ing using SAM [15,16].
Western blot and ELISA
The randomly selected 8 patients included in the verifi-
cation represent 4 control and 4 relapse patients from
all 24 patients included in the study. 30 μg of tumor
homogenate per sample were run on SDS-PAGE gels
(NuPage Bis Tris 4–12%, Invitrogen), blotted and subse-
quently incubated overnight with CAPS (sc-134298), (Santa
Cruz Biotech) and MX1 (HPA030917) (Sigma-Aldrich).
After incubation with anti-rabbit or anti-mouse IgG-HRP
Conjugate (BioRad), bands were detected using ECL™
Western Blotting Detection Reagents (Amersham). Com-
mercially available enzyme-linked immune sorbent assays
(ELISA) for quantification of CAPS (E92359Hu) and MX1
(E80763Hu) were performed according to the protocols of
the manufacturer (USCN, Cologne, Germany).
Statistical analysis of validation cohort
Differences in CAPS levels in relation to patient’s age
and tumor characteristics were analyzed with Mann-
Whitney’s test. Relapse-free survival (RFS) and breast
cancer-specific survival (BCS) were chosen as primary
end points, based on the time from diagnosis to the first
event of loco-regional or distant recurrence, and time
from diagnosis to breast cancer death, respectively. Sur-
vival curves and probabilities of RFS and BCS were esti-
mated using the Kaplan-Meier method. Hazard ratios
were calculated using Cox hazard regression analysis.
Multivariate Cox models included the variables age,
nodal status, tumor size, ER and PgR levels and CAPS
levels. The software STATISTICA 10 (StatSoft Inc., Tulsa,
OK, USA) was used for statistical calculations. P-values
less than 0.05 in two-sided tests were considered signifi-
cant. Graphpad prism 6 was used to visualize survival
curves and perform ROC and correlation analysis. Power
calculations were done using Graphpad StateMate 2.00.
Additional files
Additional file 1: Proteomics data. Protein identifications in the
discovery cohort.
Additional file 2: Principal component analysis (PCA) of
quantitative data from overlapping protein identifications between
the iTRAQ sets. (A) Both control and relapse patients, denoted C and R,
respectively. (B) Control patients (C) Relapse patients.
Additional file 3: Correlation between MS and WB data. Correlation
between MS and WB data for (A) CAPS and (B) MX1.
Johansson et al. Clinical Proteomics  (2015) 12:8 Page 9 of 10Additional file 4: Continuous vs. tertile analysis of CAPS. Table
showing continuous vs. tertile analysis of CAPS ELISA data in validation
cohort.
Additional file 5: Survial analysis for MX1. Relapse free survival (A)
and breast cancer survival (B) for MX1. MX1 was not associated with
relapse free or overall survival.
Additional file 6: ROC analysis for CAPS. ROC analysis using CAPS
measurements by ELISA for (A) relapse and (B) overall survival.
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